Kazia Therapeutics Limited

NasdaqCM KZIA

Kazia Therapeutics Limited Price to Sales Ratio (P/S) on January 15, 2025

Kazia Therapeutics Limited Price to Sales Ratio (P/S) is NA on January 15, 2025, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Kazia Therapeutics Limited 52-week high Price to Sales Ratio (P/S) is NA on None, which is NA below the current Price to Sales Ratio (P/S).
Kazia Therapeutics Limited 52-week low Price to Sales Ratio (P/S) is NA on None, which is NA below the current Price to Sales Ratio (P/S).
Kazia Therapeutics Limited average Price to Sales Ratio (P/S) for the last 52 weeks is NA.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: KZIA

Kazia Therapeutics Limited

CEO	Dr. John Edwin Friend II, M.D.
IPO Date	Jan. 6, 1999
Location	Australia
Headquarters	Three International Towers
Employees	9
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Key trends

Past 5 years